William Blair analyst Sami Corwin downgraded BioMarin (BMRN) to Market Perform from Outperform following the Q3 report. The firm cites a lack of near-term catalysts and uncertainty around Voxzogo’s revenue growth potential for the downgrade. BioMarin’s current valuation adequately reflects revenue estimates for the company’s commercial portfolio, and its clinical pipeline will not be a source of significant value creation in the near-term, the analyst tells investors in a research note.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin downgraded to Market Perform from Outperform at William Blair
- BioMarin Reports Strong Q3 Growth and Positive Outlook
- BioMarin raises FY24 non-GAAP EPS view to $3.25-$3.35 from $3.10-$3.25
- BioMarin reports Q3 non-GAAP EPS 91c, consensus 52c
- BioMarin options imply 5.0% move in share price post-earnings